Global Pharmatech, Inc.
GBLP · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -55.99 | 0.00 | 737.34 | 0.00 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 16,060.53 | -3,572.20 | -843,895.04 | -4,223.66 |
| Quality | ||||
| ROIC | -22.93% | 61.56% | 0.08% | 20.25% |
| Gross Margin | 51.24% | -20.11% | 13.53% | 4.59% |
| Cash Conversion Ratio | -12.99 | 0.29 | -58.98 | -0.34 |
| Growth | ||||
| Revenue 3-Year CAGR | 74.02% | 74.42% | 685,195.31% | 584,026.34% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 100.00% |
| Safety | ||||
| Net Debt / EBITDA | 9.12 | -2.93 | -455.26 | -1.57 |
| Interest Coverage | -92.92 | -128.68 | -0.53 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.43 | 1.12 | 4.82 | 4.18 |
| Cash Conversion Cycle | -1,810.47 | -21.58 | -75.96 | -78.76 |